Pfizer and J&J end development of Alzheimer's drug
August 6, 2012 in Alzheimer's disease & dementia
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.
The companies say their drug bapineuzumab did not improve cognition or mental function in patients with mild to moderate Alzheimer's disease when compared to placebo. It was hoped that bapineuzumab would reduce the decline in physical and mental function for patients with Alzheimer's. Current treatments can only temporarily ease symptoms of the disease.
The two companies said July 23 that the drug had failed in a different trial. All other studies are being discontinued, and Johnson & Johnson said it will take a charge of $300 million to $400 million in the third quarter.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
Alzheimer's drug fails in 1 study, 2nd continues (Update)
Jul 23, 2012 |
not rated yet |
0
-
Study examines immunotherapy and cerebrospinal fluid biomarkers in patients with Alzheimer's disease
Apr 02, 2012 |
not rated yet |
0
-
Alzheimer's drug shows promise in early trial
Jul 18, 2012 |
not rated yet |
0
-
Eli Lilly halts development of Alzheimer's drug
Aug 17, 2010 |
not rated yet |
0
-
Neuroimaging technique shows potential of bapineuzumab treatment and might be useful in assessing other drugs for Alzhei
Feb 28, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
The idea behind a reverse shock
3 hours ago
-
Guass's Law for a charge distribution
4 hours ago
-
Noise dependence
4 hours ago
-
siphon and bernouli theorum
6 hours ago
-
Hot gas expansion rate into outer space
6 hours ago
-
Magnetic field lines through copper
11 hours ago
- More from Physics Forums - Classical Physics
More news stories
A new strategy required in the search for Alzheimer's drugs?
In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...
Alzheimer's disease & dementia
May 24, 2013 |
not rated yet |
0
Alzheimer's disease, the soft target of the euthanasia debate
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
Alzheimer's disease & dementia
May 24, 2013 |
not rated yet |
2
Scientists discover cinnamon compounds' potential ability to prevent Alzheimer's
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia
May 23, 2013 |
5 / 5 (5) |
0
|
Drug reverses Alzheimer's disease deficits in mice, research confirms
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia
May 23, 2013 |
not rated yet |
0
|
Multiple research teams unable to confirm high-profile Alzheimer's study
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia
May 23, 2013 |
3 / 5 (2) |
3
|
Seniors more likely to crash when driving with pet, study finds
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
First drug to improve heart failure mortality in over a decade
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Heart failure accelerates male 'menopause'
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Feds fight morning-after pill age ruling in NY
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
